pyridoxal has been researched along with Cardiac Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sterba, M | 2 |
| Popelová, O | 2 |
| Simunek, T | 2 |
| Mazurová, Y | 2 |
| Potácová, A | 2 |
| Adamcová, M | 2 |
| Kaiserová, H | 2 |
| Ponka, P | 2 |
| Gersl, V | 2 |
2 other studies available for pyridoxal and Cardiac Diseases
| Article | Year |
|---|---|
Cardioprotective effects of a novel iron chelator, pyridoxal 2-chlorobenzoyl hydrazone, in the rabbit model of daunorubicin-induced cardiotoxicity.
Topics: Animals; Antibiotics, Antineoplastic; Blood Pressure; Body Weight; Cardiac Output; Cardiotonic Agent | 2006 |
Pyridoxal isonicotinoyl hydrazone (PIH) and its analogs as protectants against anthracycline-induced cardiotoxicity.
Topics: Animals; Antibiotics, Antineoplastic; Cardiotonic Agents; Daunorubicin; Heart Diseases; Iron Chelati | 2008 |